Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.6K
Overview
44.6K
Cancer Vaccines01:30

Cancer Vaccines

376
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
376
Cross-reactivity00:42

Cross-reactivity

31.1K
Overview
31.1K
Development of Immunocompetence01:22

Development of Immunocompetence

312
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
312
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

1.4K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy.

Journal for immunotherapy of cancer·2026
Same author

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.

Research square·2026
Same author

Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccines.

NPJ vaccines·2026
Same author

Hemodynamics and Mid-Term Clinical Outcomes Following Valve-in-Valve TAVR With Balloon-Expandable Valves.

Circulation. Cardiovascular interventions·2026
Same author

CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity.

Science immunology·2025
Same author

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Nature communications·2025

Related Experiment Video

Updated: Jul 8, 2025

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.0K

CEA vaccines.

Anchit Bhagat1, Herbert K Lyerly1,2,3, Michael A Morse1,4

  • 1Department of Surgery, Division of Surgical Sciences, Duke University, Durham, NC, USA.

Human Vaccines & Immunotherapeutics
|December 13, 2023
PubMed
Summary

Carcinoembryonic antigen (CEA) cancer vaccines show promise in breaking immune tolerance and improving outcomes. Combining viral vectors, boosting, and adjuvants may enhance efficacy in specific clinical settings.

Keywords:
CEACarcinoembryonic antigencancer vaccinesclinical trialsheterologous boostingimmunotherapyself-replicating RNA

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.0K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.7K

Related Experiment Videos

Last Updated: Jul 8, 2025

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.0K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.0K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.7K

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Carcinoembryonic antigen (CEA) is an oncofetal protein overexpressed in many carcinomas.
  • CEA is a validated target for cancer immunotherapy and vaccination due to its tumor specificity.

Purpose of the Study:

  • To review the progress of CEA vaccine development, encompassing preclinical and clinical studies.
  • To identify key insights and promising strategies for effective CEA-based cancer vaccination.

Main Methods:

  • Analysis of preclinical and clinical studies on various CEA vaccine platforms.
  • Evaluation of strategies including viral vectors, heterologous boosting, and adjuvant combinations.

Main Results:

  • CEA vaccines can successfully break immunologic tolerance and induce CEA-specific immune responses.
  • Immune responses correlate with improved clinical outcomes in a subset of patients.
  • Combinations of viral vectors, heterologous boosting, and adjuvants show particular promise.

Conclusions:

  • CEA vaccination demonstrates potential for cancer treatment by eliciting specific immunity.
  • Optimizing vaccine combinations and clinical settings is crucial for maximizing efficacy.
  • Further confirmatory studies are needed to validate early clinical trial findings.